Biosimilars Just days after gaining US Food and Drug Administration breakthrough approval for Ibrance (palbociclib) in breast cancer, US pharma giant Pfizer entered into an agreement to purchase generic drug maker Hospira for $90 per share in cash, or around $17 billion, representing about a 40% premium above Hospira’s stock price (The Pharma Letter February 5), noted GlobalData health care industry analyst Adam Dion. 7 February 2015